Psychedelic Harm Reduction and Integration in Clinical Practice
- Speaker:
- Elizabeth Nielson, PhD
- Duration:
- 1 Hour
- Language:
- Presented in EN, subtitles in EN, ES, DE, IT, and FR, handouts in EN
- Copyright:
-
27 Jul, 2022
- Product Code:
- NOS096246
- Media Type:
- Digital Seminar
Description
What do you do when a client lets you know they are going to use psychedelics on their own, as part of a ceremony, spiritual practice or because they’ve heard it can help them? Is there anything you can do to help reduce harm? And what about micro-dosing, which is gaining popularity?
Psychedelic Harm Reduction and Integration (PHRI) is a transdiagnostic and transtheoretical approach that YOU as a mental health professional can take to having conversations with people who have taken psychedelics in clinical or non-clinical settings, or who are seeking help at any stage of psychedelic use. This recording will cover the core concepts of PHRI and its applications, including discussions about microdosing, responding to requests for referrals to non-licensed providers, and working with difficult experiences.
Credit
This self-study program consists of 1.0 clock hours of continuing education instruction. Credit requirements and approvals vary by country and local regulatory bodies. Please save the course outline, the certificate of completion you receive from the activity and contact your local regulatory organization to determine specific eligibility and requirements.
Handouts
| File type | File name | Number of pages | |
|---|---|---|---|
| Attachment |
Manual Notice A seminar manual is not available for this recording. |
Speaker
Elizabeth Nielson, PhD Related seminars and products
Dr. Elizabeth Nielson is CEO and co-founder of Fluence. Her focus as a psychologist is on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson was a Site Co-Principal Investigator and therapist for an FDA-approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder, and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.
Speaker Disclosures:
Financial: Elizabeth Nielson is CEO and co-founder of Fluence International, Inc. She holds stock or stock options in AtaiBeckley, Tactogen, and GoodCap. Elizabeth Nielson receives a speaking honorarium from PESI, Inc.
Non-financial: Elizabeth Nielson has no relevant non-financial relationships.
Additional Info
Program Information
Access for Self-Study (Non-Interactive)Access never expires for this product.
Objectives
- Differentiate Psychedelic Harm Reduction and Integration from Psychedelic-assisted Therapy.
- Determine ways to intervene with clients who are using or micro-dosing psychedelics.
- Assess four theoretical pillars of the Psychedelic Harm Reduction and Integration model.
- Integrate Psychedelic Harm Reduction and Integration into the larger picture of psychedelic-assisted therapies.
Outline
- The differences between psychedelic assisted therapies & harm reduction interventions
- The Four foundations of psychedelic harm reduction interventions
- A model for integration of psychedelic applications
- The issue of micro-dosing among clients
- When clinicians are asked for referrals to non-licensed providers
- Working with difficult psychedelic experiences in psychotherapy
Target Audience
- Counselors
- Marriage & Family Therapists
- Nurses
- Nurse Practitioners
- Physicians
- Psychologists
- Social Workers
- Other Behavioral Health Professionals
Reviews
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|
Overall: 4.8
Total Reviews: 2862
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to info@pesi.eu.
Please wait ...